Sakamoto, Kazumasa
Ito, Kiyoaki
Yotsuyanagi, Hiroshi
Yatsuhashi, Hiroshi
Tanaka, Yasuhito
Hige, Shuhei
Takikawa, Yasuhiro
Ueno, Yoshiyuki
Yamamoto, Kazuhide
Imazeki, Fumio
Inoue, Jun
Kurosaki, Masayuki
Umemura, Takeji
Toyoda, Hidenori
Mita, Eiji
Michitaka, Kojiro
Maeshiro, Tatsuji
Yamada, Norie
Suetsugu, Atsushi
Kawanaka, Miwa
Seko, Yuya
Matsuura, Kentaro
Okumura, Akinori
Fukuzawa, Yoshitaka
Sugiyama, Masaya
Mizokami, Masashi
Yoneda, Masashi
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP20fk0310118, JP21fk0310118h0005, JP22fk0310502h0001)
Japan Society for the Promotion of Science (JP19K08479)
Article History
Received: 3 July 2022
Accepted: 7 September 2022
First Online: 29 September 2022
Declarations
:
: KI and MY received research funding from AbbVie, Bayer Pharma, EA pharma, Otsuka Pharmaceutical, and Sumitomo Pharmaceutical. JI received research funding from AbbVie. YT received honorariums from FUJIREBIO inc., Gilead Sciences Inc, and GlaxoSmithKline PLC. YT also received research funding from FUJIFILM Corporation, Janssen Pharmaceutical K. K., Gilead Sciences Inc, Board of Trustees of the Leland, Stanford Junior University, GlaxoSmithKline PLC., FUJIREBIO inc., Sysmex Corp. YU received honorariums from Gilead Sciences and AbbVie Inc. YU also received research funding from AbbVie Inc. MK received honorariums from Gilead Sciences, AbbVie, Chugai, Eisai, Bayer, Lilly, and Otsuka. TU received honorariums from AbbVie and also received research funding from AbbVie and Tosoh Corporation. TM received research funding from IQVIA solutions. MY received honorariums from Otsuka pharmaceutical and Sumitomo pharmaceutical.